MA45397A - Composés, compositions et procédés pour augmenter l'activité du cftr - Google Patents
Composés, compositions et procédés pour augmenter l'activité du cftrInfo
- Publication number
- MA45397A MA45397A MA045397A MA45397A MA45397A MA 45397 A MA45397 A MA 45397A MA 045397 A MA045397 A MA 045397A MA 45397 A MA45397 A MA 45397A MA 45397 A MA45397 A MA 45397A
- Authority
- MA
- Morocco
- Prior art keywords
- cftr
- compositions
- activity
- compounds
- processes
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662352672P | 2016-06-21 | 2016-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45397A true MA45397A (fr) | 2019-04-24 |
Family
ID=59337861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045397A MA45397A (fr) | 2016-06-21 | 2017-06-21 | Composés, compositions et procédés pour augmenter l'activité du cftr |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10899751B2 (fr) |
| EP (1) | EP3472156B1 (fr) |
| AU (2) | AU2017280206A1 (fr) |
| ES (1) | ES2954658T3 (fr) |
| MA (1) | MA45397A (fr) |
| WO (1) | WO2017223188A1 (fr) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202140422A (zh) | 2014-10-06 | 2021-11-01 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| US10548878B2 (en) | 2015-07-24 | 2020-02-04 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods of increasing CFTR activity |
| SG11201802798WA (en) | 2015-10-06 | 2018-05-30 | Proteostasis Therapeutics Inc | Compounds, compositions, and methods for modulating cftr |
| WO2017177124A1 (fr) | 2016-04-07 | 2017-10-12 | Proteostasis Therapeutics, Inc. | Atomes de silicone contenant des analogues d'ivacaftor |
| ES2954658T3 (es) | 2016-06-21 | 2023-11-23 | Proteostasis Therapeutics Inc | Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR |
| GEP20217329B (en) | 2016-09-30 | 2021-12-10 | Vertex Pharma | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| EA202192783A1 (ru) | 2016-12-09 | 2022-02-24 | Вертекс Фармасьютикалз Инкорпорейтед | Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора |
| WO2018180864A1 (fr) * | 2017-03-29 | 2018-10-04 | 住友精化株式会社 | Résine absorbant l'eau |
| MA54105A (fr) | 2017-06-08 | 2021-09-15 | Vertex Pharma | Méthodes de traitement de la fibrose kystique |
| IL272032B2 (en) | 2017-07-17 | 2026-04-01 | Vertex Pharma | Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and |
| MA49752A (fr) | 2017-08-02 | 2021-04-21 | Vertex Pharma | Procédés de préparation de composés de pyrrolidine |
| CA3078893A1 (fr) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Formes cristallines et compositions de modulateurs de cftr |
| KR102716244B1 (ko) | 2017-12-08 | 2024-10-14 | 버텍스 파마슈티칼스 인코포레이티드 | 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법 |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| WO2019156946A2 (fr) * | 2018-02-06 | 2019-08-15 | Research Institute At Nationwide Children's Hospital | Compositions et procédés pour améliorer la fonction cftr dans des cellules affectées par la fibrose kystique |
| RS64018B1 (sr) | 2018-02-15 | 2023-03-31 | Vertex Pharma | Makrocikli kao modulatori transmembranskog regulatora provodnosti cistične fibroze, njihove farmaceutske kompozicije, njihova upotreba u lečenju cistične fibroze i proces njihove izrade |
| WO2019195739A1 (fr) | 2018-04-05 | 2019-10-10 | Alexander Russell Abela | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique |
| WO2019200246A1 (fr) | 2018-04-13 | 2019-10-17 | Alexander Russell Abela | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
| WO2020006269A1 (fr) | 2018-06-27 | 2020-01-02 | Proteostasis Therapeutics, Inc. | Composés améliorant l'activité du protéasome |
| EP3873453A4 (fr) | 2018-10-30 | 2022-08-03 | University of Florida Research Foundation, Incorporated | Compositions d'acides aminés et méthodes de traitement de la fibrose kystique |
| WO2020115231A1 (fr) * | 2018-12-06 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions destinées au traitement des voies respiratoires atteintes de mucoviscidose |
| TWI848092B (zh) | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
| US11873300B2 (en) | 2019-08-14 | 2024-01-16 | Vertex Pharmaceuticals Incorporated | Crystalline forms of CFTR modulators |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| US20220323425A1 (en) | 2019-08-28 | 2022-10-13 | The Regents Of The University Of California | Co-potentiators for therapy of cystic fibrosis caused by minimal function cftr mutants |
| AU2021217225A1 (en) * | 2020-02-07 | 2022-10-06 | University Of South Florida | Inhibition of beta-arrestin oligomerization in tauopathy |
| WO2022036060A1 (fr) | 2020-08-13 | 2022-02-17 | Vertex Pharmaceuticals Incorporated | Formes cristallines de modulateurs de cftr |
| EP3970718A1 (fr) * | 2020-09-18 | 2022-03-23 | Charité - Universitätsmedizin Berlin | Nouvelle utilisation médicale des modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique (cftr) |
| US12612416B2 (en) | 2020-10-07 | 2026-04-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2023006770A (es) | 2020-12-10 | 2023-08-14 | Vertex Pharma | Metodos de tratamiento para fibrosis quistica. |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336264A (en) | 1980-06-19 | 1982-06-22 | Eli Lilly And Company | 1-Benzoyl-3-(isoxazolyl or benzisoxazolyl)-ureas and insecticidal use thereof |
| DE3812225A1 (de) | 1988-04-13 | 1989-10-26 | Basf Ag | Isoxazol(isothiazol)-5-carbonsaeureamide |
| WO1997005131A1 (fr) | 1995-08-02 | 1997-02-13 | J. Uriach & Cia. S.A. | Nouveaux carboxamides a activite antifongique |
| DE69628705T2 (de) | 1995-08-24 | 2004-05-13 | Basf Ag | Isoxazole- und Isothiazole-5-carboxamid Derivate, deren Herstellung und deren Verwendung als Herbizide |
| PT957099E (pt) | 1998-04-15 | 2003-02-28 | Pfizer Prod Inc | Carboxamidas heterociclicas |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| AU2003234464B2 (en) | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| US7598412B2 (en) | 2003-10-08 | 2009-10-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| CN101675928A (zh) | 2003-11-14 | 2010-03-24 | 沃泰克斯药物股份有限公司 | 可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑 |
| WO2005077373A2 (fr) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Nouveau traitement du reflux gastro-oesophagien pathologique ii |
| WO2005077345A1 (fr) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Composes pour le traitement de la maladie du reflux gastro-oesophagien |
| JP2008503446A (ja) | 2004-05-06 | 2008-02-07 | プレキシコン，インコーポレーテッド | Ｐｄｅ４ｂ阻害剤及びその使用 |
| SE0401969D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidine derivatives |
| US20060100226A1 (en) | 2004-09-10 | 2006-05-11 | Sikorski James A | 2-Thiopyrimidinones as therapeutic agents |
| DE102004051277A1 (de) | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
| ATE488496T1 (de) | 2005-06-22 | 2010-12-15 | Pfizer Prod Inc | Histamin-3-rezeptorantagonisten |
| WO2007075896A2 (fr) | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Inhibiteurs de cytokine heterocycliques |
| KR101394245B1 (ko) | 2005-12-30 | 2014-05-14 | 에스케이바이오팜 주식회사 | 아이속사졸 유도체 및 이의 용도 |
| WO2007086584A1 (fr) | 2006-01-30 | 2007-08-02 | Meiji Seika Kaisha, Ltd. | NOUVEL INHIBITEUR DE FabK ET DE FabI/K |
| TW200815351A (en) | 2006-05-02 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
| WO2008046072A2 (fr) | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Inducteurs chimiques de la neurogénèse |
| US8193225B2 (en) | 2006-10-13 | 2012-06-05 | The Board Of Regents Of The University Of Texas System | Isoxazole amides, derivatives and methods of chemical induction of neurogenesis |
| EP2076513A1 (fr) | 2006-10-20 | 2009-07-08 | Irm Llc | Compositions et procédés de modulation de récepteurs de c-kit et de facteur de croissance dérivé de plaquettes (pdgfr) |
| WO2008070739A1 (fr) | 2006-12-06 | 2008-06-12 | Cytokinetics, Inc. | Activateurs de ksp |
| CN101778845B (zh) | 2007-06-29 | 2014-06-25 | 爱思开生物制药株式会社 | 用于预防和治疗再狭窄的包含异噁唑衍生物的药物组合物 |
| WO2009011850A2 (fr) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Nouveaux composés thérapeutiques |
| CN101796036A (zh) | 2007-08-02 | 2010-08-04 | 欧加农股份有限公司 | 作为trpv1调节剂的5-苯基异噁唑-3-甲酰胺衍生物 |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8236838B2 (en) | 2008-04-21 | 2012-08-07 | Institute For Oneworld Health | Compounds, compositions and methods comprising isoxazole derivatives |
| US20090318429A1 (en) | 2008-04-28 | 2009-12-24 | Institute For Oneworld Health | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives |
| US20120095002A1 (en) | 2009-02-04 | 2012-04-19 | N.V. Organon | Isoxazole-5-carboxamide derivatives |
| CA2755120C (fr) | 2009-03-11 | 2017-05-16 | Kyorin Pharmaceutical Co., Ltd. | 7-cycloalkylaminoquinolones comme inhibiteurs de la gsk-3 |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| IN2012DN00352A (fr) | 2009-06-16 | 2015-08-21 | Bikam Pharmaceuticals Inc | |
| WO2011008931A2 (fr) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Composés arylpyrimidines et thérapie de combinaison comprenant ceux-ci pour traiter une mucoviscidose et des troubles apparentés |
| US9212177B2 (en) | 2009-08-05 | 2015-12-15 | Versitech Limited | Antiviral compounds and methods of making and using thereof |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| US8569899B2 (en) | 2009-12-30 | 2013-10-29 | Stmicroelectronics, Inc. | Device and method for alignment of vertically stacked wafers and die |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| EP2593447B1 (fr) | 2010-07-15 | 2016-08-17 | Bayer Intellectual Property GmbH | Composés de 3-pyridyl-heteroarylcarboxamide comme d'agents de lutte contre les nuisibles |
| TR201807311T4 (tr) | 2011-03-10 | 2018-06-21 | Daiichi Sankyo Co Ltd | Dispiropirolidin derivesi. |
| CA2736441A1 (fr) | 2011-04-06 | 2012-10-06 | The Regents Of The University Of California | Pyrazolylthiazoles en tant que correcteurs du regulateur de la conductivite transmembranaire de la proteine .delta.f508 de la fibrose kystique |
| HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
| ME03652B (fr) | 2011-05-18 | 2020-07-20 | Vertex Pharmaceuticals Europe Ltd | Dérivés deutérés d'ivacaftor |
| EA201490406A1 (ru) | 2011-07-29 | 2014-07-30 | Кариофарм Терапевтикс, Инк. | Модуляторы ядерного транспорта и их применение |
| JP6165733B2 (ja) | 2011-09-16 | 2017-07-19 | ノバルティス アーゲー | Ｎ−置換ヘテロシクリルカルボキサミド類 |
| CN103946221B (zh) | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
| US8623860B2 (en) | 2011-12-30 | 2014-01-07 | Boehringer Ingelheim International Gmbh | Azetidine derivatives, pharmaceutical compositions and uses thereof |
| AU2013221420B2 (en) | 2012-02-16 | 2017-07-13 | Corteva Agriscience Llc | Methods of producing sulfilimine compounds |
| UA110436C2 (en) | 2012-03-06 | 2015-12-25 | Zoetis Llc | Antibacterial phenol compounds |
| WO2013146970A1 (fr) | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | Nouveau dérivé de quinoléine |
| AU2013319788B2 (en) | 2012-09-24 | 2019-04-11 | Yissum Reasearch Development Company of the Hebrew University Of Jerusalem Ltd. | Restoration of the CFTR function by splicing modulation |
| CA2891965A1 (fr) | 2012-11-20 | 2014-05-30 | Discoverybiomed, Inc. | Correcteurs de cftr bicycliques et tricycliques a petites molecules |
| US9676779B2 (en) | 2012-11-20 | 2017-06-13 | Discoverybiomed, Inc. | Small molecule CFTR correctors |
| EP2968323A4 (fr) | 2013-03-13 | 2016-12-14 | Flatley Discovery Lab | Composés de pyridazinone et procédés pour le traitement de fibrose kystique |
| EP2968285A4 (fr) | 2013-03-13 | 2016-12-21 | Flatley Discovery Lab | Composés et procédés pour le traitement de fibrose kystique |
| CA2903103C (fr) | 2013-03-15 | 2020-06-09 | Discoverybiomed, Inc. | Derives de coumarine et leurs methodes d'utilisation dans le traitement de la fibrose kystique, de la bronchopneumopathie chronique obstructive et des troubles lies a des proteine s mal repliees |
| EP2968987A4 (fr) | 2013-03-15 | 2017-04-26 | Vertex Pharmaceuticals Inc. | Correcteurs agissant par l'intermédiaire de msd1 de la protéine cftr |
| WO2014176553A1 (fr) | 2013-04-26 | 2014-10-30 | Vertex Pharmaceuticals Incorporated | Correcteurs agissant par le biais du domaine msd1 de la protéine cftr |
| CA3122383A1 (fr) | 2013-05-07 | 2014-11-13 | Galapagos Nv | Nouveaux composes et leurs compositions pharmaceutiques pour le traitement de la mucoviscidose. |
| WO2014181287A1 (fr) | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Composés hétérocyclyliques et leurs utilisations |
| AU2014302458A1 (en) * | 2013-06-26 | 2015-12-24 | Proteostasis Therapeutics, Inc. | Methods of modulating CFTR activity |
| US9920073B2 (en) | 2013-10-04 | 2018-03-20 | Drexel University | Compositions useful for inhibiting HIV-1 infection and methods using same |
| AU2015229117A1 (en) | 2014-03-13 | 2016-09-29 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
| CA2942386A1 (fr) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Composes, compositions et procedes pour augmenter l'activite du cftr |
| EP3157917B1 (fr) | 2014-06-19 | 2020-03-18 | Proteostasis Therapeutics, Inc. | Composés, compositions et procédés pour augmenter l'activité du cftr |
| WO2016054560A1 (fr) * | 2014-10-02 | 2016-04-07 | Flatley Discovery Lab | Composés isoxazoles et procédés pour le traitement de la fibrose kystique |
| WO2016105468A1 (fr) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Dérivés de 3-hétéroarylisoxazol-5-amide carboxylique utiles dans le traitement, entre autres, d'une fibrose kystique |
| WO2016105477A1 (fr) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc | Dérivés d'amides 5-phényl- ou 5-hétéroarylthiazol-2-carboxyliques servant au traitement, entre autres, de la fibrose cystique |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| US10738011B2 (en) | 2014-12-23 | 2020-08-11 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| US20180147187A1 (en) | 2015-01-12 | 2018-05-31 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| US10548878B2 (en) | 2015-07-24 | 2020-02-04 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods of increasing CFTR activity |
| US20190022071A1 (en) | 2015-08-31 | 2019-01-24 | Proteostasis Therapeutics, Inc. | Methods of treating pulmonary diseases and disorders |
| SG11201802798WA (en) | 2015-10-06 | 2018-05-30 | Proteostasis Therapeutics Inc | Compounds, compositions, and methods for modulating cftr |
| MA44126A (fr) | 2015-12-22 | 2018-10-31 | Proteostasis Therapeutics Inc | Méthodes de traitement de maladies et troubles pulmonaires |
| WO2017177124A1 (fr) | 2016-04-07 | 2017-10-12 | Proteostasis Therapeutics, Inc. | Atomes de silicone contenant des analogues d'ivacaftor |
| AU2017264612A1 (en) | 2016-05-09 | 2018-11-22 | Proteostasis Therapeutics, Inc. | Methods of identifying CFTR modulators |
| ES2954658T3 (es) | 2016-06-21 | 2023-11-23 | Proteostasis Therapeutics Inc | Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR |
-
2017
- 2017-06-21 ES ES17739769T patent/ES2954658T3/es active Active
- 2017-06-21 WO PCT/US2017/038521 patent/WO2017223188A1/fr not_active Ceased
- 2017-06-21 MA MA045397A patent/MA45397A/fr unknown
- 2017-06-21 AU AU2017280206A patent/AU2017280206A1/en not_active Abandoned
- 2017-06-21 EP EP17739769.2A patent/EP3472156B1/fr active Active
- 2017-06-21 US US16/311,397 patent/US10899751B2/en active Active
-
2021
- 2021-08-10 AU AU2021215136A patent/AU2021215136B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3028966A1 (fr) | 2017-12-28 |
| EP3472156B1 (fr) | 2023-06-07 |
| AU2017280206A1 (en) | 2019-01-17 |
| US10899751B2 (en) | 2021-01-26 |
| ES2954658T3 (es) | 2023-11-23 |
| AU2021215136A1 (en) | 2021-09-02 |
| AU2021215136B2 (en) | 2023-07-27 |
| US20200010461A1 (en) | 2020-01-09 |
| EP3472156A1 (fr) | 2019-04-24 |
| WO2017223188A1 (fr) | 2017-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41253A (fr) | Composés, compositions et procédés pour augmenter l'activité du cftr | |
| MA42488A (fr) | Composés, compositions et procédés pour augmenter l'activité du cftr | |
| MA49061A (fr) | Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr | |
| MA50636A (fr) | Compositions et procédés pour inhiber l'activité d'arginase | |
| EP3442488A4 (fr) | Compositions pour l'application topique de composés | |
| IL283042A (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| MA44734A (fr) | Composés et compositions destinés au traitement d'états associés à une activité de nlrp | |
| EP3353309A4 (fr) | Compositions et méthodes pour l'édition génomique | |
| MA45670A (fr) | Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome | |
| EP3386550A4 (fr) | Procédés et compositions pour la fabrication et l'utilisation d'acides nucléiques de guidage | |
| MA56008A (fr) | Composés et compositions pour traiter des états associés à une activité de nlrp | |
| EP3431075A4 (fr) | Forme galénique d'édaravone | |
| EP3267995A4 (fr) | Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement de la fibrose | |
| MA46791A (fr) | Composés et procédés pour réduire l'expression d'atxn3 | |
| EP3443094A4 (fr) | Procédés de réduction de l'expression de c9orf72 | |
| EP3519572A4 (fr) | Composés et procédés pour réduire l'expression de tau | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| EP3412344A4 (fr) | Composition d'agent extincteur | |
| EP3645013A4 (fr) | Compositions et procédés pour inhiber l'expression de hmgb1 | |
| EP3250230A4 (fr) | Modulateurs d'activité du complément | |
| PL3487491T3 (pl) | Kompozycje do zwiększenia aktywności mózgu | |
| EP3530722A4 (fr) | Composition d'agent nettoyant | |
| EP3538219A4 (fr) | Compositions topiques destinées au traitement de l'acné | |
| EP3261631A4 (fr) | Inhibition de l'activité d'olig2 | |
| EP3362578A4 (fr) | Méthodes d'évaluation génomique du bétail |